[go: up one dir, main page]

EA201591276A1 - Фармацевтическая композиция с улучшенной биодоступностью - Google Patents

Фармацевтическая композиция с улучшенной биодоступностью

Info

Publication number
EA201591276A1
EA201591276A1 EA201591276A EA201591276A EA201591276A1 EA 201591276 A1 EA201591276 A1 EA 201591276A1 EA 201591276 A EA201591276 A EA 201591276A EA 201591276 A EA201591276 A EA 201591276A EA 201591276 A1 EA201591276 A1 EA 201591276A1
Authority
EA
Eurasian Patent Office
Prior art keywords
improved bioavailability
pharmaceutical composition
fluorophenyl
chloro
compounds
Prior art date
Application number
EA201591276A
Other languages
English (en)
Other versions
EA028009B1 (ru
Inventor
Стив Ломуссио
Хуа Ма
Майкл Аллен Мэтчетт
Харпреет К. Сэндху
Навнит Харговиндас Шах
Ю-Э Чжан
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50023547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201591276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of EA201591276A1 publication Critical patent/EA201591276A1/ru
Publication of EA028009B1 publication Critical patent/EA028009B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к твердым дисперсиям слаборастворимых в воде соединений, в частности 4-{[(2R,3S,4R,5S)-4-(4-хлор-2-фторфенил)-3-(3-хлор-2-фторфенил)-4-циано-5-(2,2-диметилпропил)пирролидин-2-карбонил]амино}-3-метоксибензойной кислоты, образуемым совместным осаждением с растворителем или сушкой распылением, что дает в результате улучшенные биодоступность, безопасность и переносимость указанных соединений.
EA201591276A 2013-01-22 2014-01-20 Фармацевтическая композиция с улучшенной биодоступностью EA028009B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361755074P 2013-01-22 2013-01-22
PCT/EP2014/050974 WO2014114575A1 (en) 2013-01-22 2014-01-20 Pharmaceutical composition with improved bioavailability

Publications (2)

Publication Number Publication Date
EA201591276A1 true EA201591276A1 (ru) 2016-01-29
EA028009B1 EA028009B1 (ru) 2017-09-29

Family

ID=50023547

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201591276A EA028009B1 (ru) 2013-01-22 2014-01-20 Фармацевтическая композиция с улучшенной биодоступностью

Country Status (24)

Country Link
US (2) US9427427B2 (ru)
EP (1) EP2948141B1 (ru)
JP (1) JP6192244B2 (ru)
KR (1) KR101737250B1 (ru)
CN (3) CN104936589A (ru)
AR (1) AR094548A1 (ru)
AU (1) AU2014210103B2 (ru)
BR (1) BR112015015758B1 (ru)
CA (1) CA2892025C (ru)
CL (1) CL2015001649A1 (ru)
CR (1) CR20150287A (ru)
EA (1) EA028009B1 (ru)
HK (1) HK1211217A1 (ru)
IL (1) IL239657B (ru)
MA (1) MA38289A1 (ru)
MX (1) MX372668B (ru)
MY (1) MY192032A (ru)
NZ (1) NZ708272A (ru)
PE (1) PE20151335A1 (ru)
PH (1) PH12015501620B1 (ru)
SG (1) SG11201504499VA (ru)
UA (1) UA116004C2 (ru)
WO (1) WO2014114575A1 (ru)
ZA (1) ZA201504187B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767872C2 (ru) * 2017-07-04 2022-03-22 Цзянсу Хэнжуй Медсин Ко., Лтд. Фармацевтическая композиция и способ ее получения

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3131878A1 (en) * 2014-04-15 2017-02-22 F. Hoffmann-La Roche AG Solid forms of a pharmaceutically active compound
PT107846B (pt) * 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
HUE051888T2 (hu) * 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
CA2969656A1 (en) 2014-12-05 2016-06-09 Aragon Pharmaceuticals, Inc. Solid formulations of arn-509 and hydroxypropyl methylcellulose acetate succinate
AU2015358497B2 (en) 2014-12-05 2021-04-29 Aragon Pharmaceuticals, Inc. Anticancer compositions
EP3307246A1 (en) 2015-06-09 2018-04-18 Capsugel Belgium NV Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
CA3022777A1 (en) * 2017-04-21 2018-10-25 Bio-Synectics Inc. Method for preparing nanoparticle of active ingredient using lipid as lubricant in milling process
CA3081358A1 (en) * 2017-11-10 2019-05-16 Dispersol Technologies, Llc Improved drug formulations
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
WO2019213106A1 (en) 2018-04-30 2019-11-07 Teva Pharmaceuticals International Gmbh Solid state forms of idasanutlin
TW202444718A (zh) * 2019-01-25 2024-11-16 英屬開曼群島商百濟神州有限公司 作為ｂ－ｒａｆ激酶二聚體抑制劑之化合物及其製備方法
SG11202109503TA (en) * 2019-03-11 2021-09-29 Ptc Therapeutics Inc Compound form having enhanced bioavailability and formulations thereof
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
MX2021014402A (es) * 2019-05-31 2022-02-14 Jiangsu Hengrui Medicine Co Dispersion de solidos y metodo de preparacion de los mismos.
JP7634525B2 (ja) * 2019-09-23 2025-02-21 バイオノミクス リミテッド 治療用製剤およびその使用
CN114727963B (zh) * 2019-12-02 2024-12-27 阿斯利康(瑞典)有限公司 6-(2-氯-6-甲基吡啶-4-基)-5-(4-氟苯基)-1,2,4-三嗪-3-胺的固体药物配制品
CA3163951A1 (en) * 2019-12-20 2021-06-24 Intervet International B.V. A pharmaceutical composition of a pyrazole compound dispersed in a polymer matrix
TWI874667B (zh) * 2020-06-05 2025-03-01 美商應用材料股份有限公司 經塗佈的藥物組成物及製備彼之方法
CN112022812B (zh) * 2020-11-03 2021-01-29 上海亚盛医药科技有限公司 一种包含杂环类化合物的组合物、其制备方法和应用
IL303390A (en) 2020-12-03 2023-08-01 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
US12031128B2 (en) 2021-04-07 2024-07-09 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
EP4119128A1 (en) * 2021-07-13 2023-01-18 Dr. Falk Pharma Gmbh Pharmaceutical composition for the oral administration of poorly soluble drugs comprising an amorphous solid dispersion
EP4561539A1 (en) * 2022-07-26 2025-06-04 Pharma Cinq, LLC Uridine triacetate amorphous formulation and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
CZ293841B6 (cs) 1996-05-20 2004-08-18 Janssenápharmaceuticaán@Áv Částice s obsahem itrakonazolu
SE507313C2 (sv) 1997-02-25 1998-05-11 Neste Oy Förfarande för framställning av ftalsyraanhydrid
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
NZ512287A (en) 1998-12-11 2002-12-20 Pharmasolutions Inc Pharmaceutical compositions comprising a lipophilic drug in a propylene glycol ester of a higher fatty acid carrier, where 60% of the ester is a monoester
DE60039377D1 (de) 1999-02-09 2008-08-21 Pfizer Prod Inc Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit
US6057289A (en) 1999-04-30 2000-05-02 Pharmasolutions, Inc. Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system
EP1302201A4 (en) 2000-07-17 2007-09-05 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY
US6555558B2 (en) 2000-10-31 2003-04-29 Boehringer Ingelheim Pharmaceuticals, Inc. Oral dosage self-emulsifying formulations of pyranone protease inhibitors
EP1543841A4 (en) 2002-08-15 2011-03-16 Yunqing Liu SOLID PHARMACEUTICAL NANO FORMULATION AND MANUFACTURING METHOD THEREFOR
US7438261B2 (en) 2004-09-09 2008-10-21 David R. Porter Stratospheric balloon utilizing electrostatic inflation of walls
EA018811B1 (ru) 2006-03-20 2013-10-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения твердой дисперсии лекарственного средства и твердые дисперсии лекарственного средства, полученные этим способом
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
KR20170058465A (ko) 2009-04-03 2017-05-26 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
CN102871950B (zh) * 2011-07-15 2016-04-20 上海睿智化学研究有限公司 一种熊果酸固体分散体及其制备方法
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
US20140128431A1 (en) * 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2767872C2 (ru) * 2017-07-04 2022-03-22 Цзянсу Хэнжуй Медсин Ко., Лтд. Фармацевтическая композиция и способ ее получения

Also Published As

Publication number Publication date
KR101737250B1 (ko) 2017-05-17
IL239657B (en) 2019-05-30
CN112370427A (zh) 2021-02-19
BR112015015758A2 (pt) 2018-06-19
ZA201504187B (en) 2018-11-28
US9427427B2 (en) 2016-08-30
EP2948141A1 (en) 2015-12-02
CA2892025A1 (en) 2014-07-31
CN104936589A (zh) 2015-09-23
AU2014210103B2 (en) 2018-09-06
EP2948141B1 (en) 2025-05-14
US10034854B2 (en) 2018-07-31
MY192032A (en) 2022-07-24
PH12015501620B1 (en) 2018-08-24
MA38289A1 (fr) 2017-01-31
NZ708272A (en) 2020-07-31
MX2015008911A (es) 2015-10-22
SG11201504499VA (en) 2015-08-28
JP2016505029A (ja) 2016-02-18
PH12015501620A1 (en) 2015-09-28
BR112015015758B1 (pt) 2022-01-04
CN112353762A (zh) 2021-02-12
MX372668B (es) 2020-04-23
PE20151335A1 (es) 2015-09-18
EA028009B1 (ru) 2017-09-29
IL239657A0 (en) 2015-08-31
KR20150097792A (ko) 2015-08-26
US20140206742A1 (en) 2014-07-24
EP2948141C0 (en) 2025-05-14
UA116004C2 (uk) 2018-01-25
BR112015015758B8 (pt) 2021-10-13
HK1211217A1 (en) 2016-05-20
AR094548A1 (es) 2015-08-12
AU2014210103A1 (en) 2015-06-11
CR20150287A (es) 2015-09-01
JP6192244B2 (ja) 2017-09-06
CL2015001649A1 (es) 2015-10-23
CA2892025C (en) 2022-02-15
US20170000764A1 (en) 2017-01-05
WO2014114575A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EA201591276A1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
WO2012168430A3 (en) Polypeptides
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
CL2015001358A1 (es) Potenciadores del cftr deuterados
BR112017009405A2 (pt) composições antibióticas.
EA201892007A1 (ru) 3-дезоксипроизводное и фармацевтические композиции на его основе
WO2015013330A3 (en) Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof
EA201491644A1 (ru) Фармацевтические композиции
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
EA201691146A1 (ru) Иммуногенное соединение
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
EA201890771A1 (ru) Соли и твердые формы монобактамного антибиотика
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EP4414376A3 (en) Novel depsipeptide and uses thereof
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
HK1248069A1 (zh) 去乙酰氧基微管溶素h及其類似物
EA201691795A1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
BR112014025041B8 (pt) Composição farmacêutica
EA201300990A1 (ru) Парентеральное введение тапентадола
EA201070691A1 (ru) Амидные соединения в качестве активаторов противовирусных препаратов
WO2016209978A3 (en) Thiol-ene based peptide stapling and uses thereof
EA201591795A1 (ru) Бицикло[2.2.1]-кислоты в качестве модуляторов рецептора gpr120

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM